Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Karyopharm Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-136.2 Mil. Karyopharm Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $240.4 Mil.
Therefore, Karyopharm Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was -0.57.
The historical rank and industry rank for Karyopharm Therapeutics's Equity-to-Asset or its related term are showing as below:
KPTI'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.57 Med: 0.35 Max: 0.94
Current: -0.57
During the past 13 years, the highest Equity to Asset Ratio of Karyopharm Therapeutics was 0.94. The lowest was -0.57. And the median was 0.35.
KPTI's Equity-to-Asset is ranked worse than 90.16% of 1565
companies
in the Biotechnology industry
Industry Median: 0.67
vs KPTI: -0.57
Karyopharm Therapeutics Equity-to-Asset Historical Data
The historical data trend for Karyopharm Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Karyopharm Therapeutics's Equity-to-Asset
For the Biotechnology subindustry, Karyopharm Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Karyopharm Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Karyopharm Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Karyopharm Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Karyopharm Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Karyopharm Therapeutics Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Karyopharm Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Karyopharm Therapeutics (Karyopharm Therapeutics) Business Description
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
KPTI has been successfully added to your 